JLABS@Toronto accepting applications now for pharma/devices/consumer/digital health companies



Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael’s Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto.

JLABS@Toronto accepting applications now for pharma/devices/consumer/digital health companies

Johnson & Johnson Innovation invites you to apply to become a JLABS resident by submitting NON-CONFIDENTIAL INFORMATON ONLY.

JLABS Companies

These innovative companies are working to rapidly deliver better solutions to the world’s healthcare challenges.

see more here


Leave a comment

October 3, 2015 · 11:48 am

OXFORD & HARVARD & CHINESE University Guanghua joined to launch an Executive Program

indexBusiness schools at three of the world’s top universities have launched an executive programme to help develop China’s family businesses, which dominate the country’s private sector. High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our Ts&Cs and Copyright Policy for more detail. Email ftsales.support@ft.com to buy additional rights. http://www.ft.com/cms/s/0/cd764aa6-5188-11e5-8642-453585f2cfcd.html#ixzz3krx8kIzO

The three institutions span the globe: the Guanghua school at Peking University, Oxford university’s Saïd Business School and Harvard Business School. The programme details were announced in Beijing, where the first module will take place in March 2016. A further two modules will be taught in the US and the UK.

The collaboration is the first time the three institutions have worked together on an executive programme, though Saïd dean Peter Tufano was a long-term academic at HBS before moving to Oxford in 2011. He has recently announced that he will serve for a second term at Said.

Read More Here on Financial Times


Leave a comment

September 5, 2015 · 1:10 pm





BUY TICKETS: http://www.toronto2015.org/

Leave a comment

July 12, 2015 · 12:21 pm



Founded in 1998, Oxford PharmaGenesis is proud to be a leading independently owned consultancy in a sector increasingly populated by corporate communications conglomerates.

Now employing more than 120 dedicated HealthScience experts in offices in Oxford, London, Basel and Philadelphia, Oxford PharmaGenesis is a preferred supplier to 7 of the top 10 global pharmaceutical companies. Our diverse client list comprises over 50 healthcare organizations, including specialist devices, diagnostics and nutraceuticals companies, and professional societies, patient groups and academic institutions.

What drives the team?

They are a team of passionate and experienced individuals wholly committed to helping our clients to bring new treatments to the world in areas of unmet medical need. They aim to employ only the very best people.

Leave a comment

July 7, 2015 · 12:30 pm



TellSpec’s Food Scanner Technology

TellSpec’s food sensor uses the Texas Instruments’ DLP technology. This technology allows our scanner to have an excellent performance due to a higher signal to noise ratio as well as a more accurate spectrum acquisition. We believe that TI ‘s DLP technology applied to spectroscopy brings amazing new opportunities for the exploding Sensor Industry, and we are proud to be working with Texas Instrument.

Leave a comment

July 7, 2015 · 12:01 pm


D2DD2D works with the financial services industry, government agencies, national non-profit groups, grassroots community agencies, and public policy organizations to generate promising ideas, pilot test financial products and services, build awareness of the needs and potential of low-income communities, and advocate inclusive social and economic policies.

D2D uses a four-stage innovation process to bring policies and products to market that increase the financial security and opportunity of low- and moderate-income households.

1) Ideate: Seek out and observe new consumer finance trends.
2) Innovate: Create new consumer financial products, services, and public policies.
3) Incubate: Pilot test and evaluate the most promising ideas.
4) Stimulate: Provoke private and public financial system participants to scale tested concepts.

Doorways to Dreams (D2D) Fund strengthens the financial opportunity and security of low and moderate income consumers by innovating, incubating and stimulating new financial products and policies. READ MORE

Leave a comment

March 17, 2015 · 4:55 pm

The CEO Report

indexby Peter Tufano, Dean of Oxford Business School,

January 2015 was an exciting one for the School. I was at the World Economic Forum (WEF) in Davos with colleagues to announce three important initiatives for the School.

The first was the launch of ‘The CEO Report’, the result of a global research project that we conducted in partnership with Heidrick & Struggles that focuses on 152 interviews carried out with CEOs of global companies.  The CEO Report was launched at a breakfast briefing on Wednesday 21 January by Professor Tim Morris, and sparked a lively debate among a panel of CEOs composed of Ilene Gordon, Chairman, President and CEO of Ingredion; Arne Sorenson, President and CEO, Marriott International; and Klaus Kleinfeld, Chairman and CEO, Alcoa, moderated by Matthew Bishop, Globalisation Editor of The Economist.

The report identifies six critical capabilities CEOs need for success in a changing and complex global environment such as the ability to harness doubt constructively, and to anticipate interactions between seemingly disconnected global trends and identify potential issues and opportunities – which the team call ‘ripple intelligence’. In addition to Tim Morris, the full research team included Andrew White, Michael Smets, Amanda Moss Cowan, Andromachi Athanasopoulou, and Ted Malloch.

Secondly, we announced a piece of research we have just started with EY that is looking at the link between organisational purpose and the potential positive impact on transformation, innovation and inclusive growth. Marc Ventresca introduced the EY research at a breakfast briefing on Thursday 22 January where Sir Richard Branson introduced a prestigious panel of CEOs whose companies have made purpose a core part of their operations – Arianna Huffington, President & Editor-in-Chief, Huffington Post Media; Antony Jenkins, Group CEO, Barclays; Paul Polman, CEO, Unilever; Irene Rosenfeld, Chairman & CEO, Mondelez International; and Mark Weinberger, Global Chairman and CEO, EY, with moderator Stephanie Ruhle, Bloomberg. The research team includes Oxford colleagues Andrew White and Matthew Grimes. This work will continue in collaboration with the newly-announced EY Beacon Institute for Purpose.

Third, I am delighted to announce a collaboration with the Global Shapers Community which will strengthen our shared vision to create new solutions to world-scale social, environmental, political and economic challenges. The 4,659 young people worldwide who have been designated Global Shapers by the WEF will be encouraged to apply for two new dedicated scholarships for our MBA programme. We look forward to Shapers from the 402 hubs around the globe applying to the school in the coming years.

In addition, WEF launched its ‘Shaping Davos’ sessions this year designed to include participants from around the world in forum conversations.  The inaugural Shaping Davos panel was chaired by Stephan Chambers (on Trust in Public Private Partnerships)  and enaged panellists from Accra, Kathmandu, Luxembourg, and Addis Ababa (http://shapingdavos.org/).

Our work should produce results, and this month more of our research is in the news. Our research with Heidrick & Struggles was profiled very positively in the Financial Times; Tim Jenkinson won one of the top honours for his research; and President Obama signed into law the American Savings Promotion Act, which turns one of my own streams of research into reality. We seek to turn ideas into action.

As well as partnering in research, we also forge links in person. The OBA New Year Dinner will take place on 7 February 2015 at the Institute of Directors.  Our speaker will be Orna NiChionna, the Chair of our Business Advisory Council.  Among her other many accomplishments, Orna chairs the Advisory Board of Eden McCallum, profiled recently in The Economist as being at the forefront of “on-demand workplaces.”


Peter Tufano

Category: Dean’s Dialogue
Tags: Dean, Tufano, Research

Leave a comment

March 17, 2015 · 4:31 pm

OBA Boston Chapter

Virtual nations: new communication challenges for states, business, society

Tue, 27 Jan, 2015 18:00 – 19:30

Pre-registration at least 2 days in advance and a photo ID are required to enter the Consulate. 

The OBA cordially invites you (whether you are an alumnus or not) to the second OBA Boston Lecture with a seminar entitled:

“Virtual nations: new communication challenges for states, business, and society”

Speaker: Dr Simon Moore, Associate Professor of Information Design & Corporate Communications at Bentley College and Oxford DPhil.

From the Bentley website: “Specializes in public affairs, issues and risk management, crisis planning, developing new business proposals and environmental communication. Created and taught public relations and crisis communications courses at the undergraduate and graduate levels in Britain, Canada and United States. Published, presented and consulted in Britain, Canada and the United States. Author of An Invitation to Public Relations and Public Relations and the History of Ideas; co-author of Effective Crisis Communication: Worldwide Principles and Practice, Global Technology and Corporate Crisis.”

About the Oxford Business Alumni Lecture Series
Businesses operate in complex contexts affected by economic climates, political trends, cultural values, legal developments, and technological changes. The OBA Lecture Series seeks to explore the practice and theory of business and management across disciplines and contexts. Addressing an audience of Oxford business school graduates, Oxford alumni, and friends of Oxford based in and around Boston, the lecture series will invite speakers and experts from a wide range of fields – economics, political science, religion, technology, law, entrepreneurship and others – to speak on their impact on business and management in an increasingly networked and diverse world.

Leave a comment

December 21, 2014 · 3:11 pm



Safe Water for a Healthy World

BioString is developing an integrated and automated device that allows E. coli testing to be performed on site, within a matter of hours, replacing the standard multi-day labour-intensive methods. Faster and more accurate water testing allows municipalities to identify contaminated water sources more quickly, thus eliminating public health risks and increasing the efficiency of beach and water management systems.




BreqLabs is commercializing a novel sensor glove device that can track very accurately and at high speed the movements of the hand. This technology can help enhance the computer gaming experience and training tools, provide handsfree computer access and simulators, or assist people with pain or mobility limitations.



Discovery by choice not by chance

Chematria makes software that helps pharmaceutical companies determine which molecules can become medicines. With Chematria’s proprietary approach to molecular docking simulations, pharmaceutical researchers can confidently predict potent molecules for novel biological targets, thereby enabling faster drug development for a fraction of the price of wet-lab experiments.

Leave a comment

December 8, 2014 · 8:04 pm



Sciventions is a platform designed to connect researchers around the world together, may they work in academia, a small company or a large firm. We offer a platform where scientists and researchers can sell their ideas and specialized products and services that are either not fully developed to be commercialized or are otherwise too small in volume to be sold separately. These products are tools that are used every day in the lab and are not available commercially and need to be implemented in house.

Our goal is to

1. Offer a platform where scientist fresh ideas and new products can be sold and tested for a possible market.

2. Improve the collaboration between scientists and researchers by introducing them to the products and services that their colleagues can offer them.


Leave a comment

Filed under Uncategorized



CivicAction with the support of its partner, NPower Canada welcomed its first cohort into the Technology Services Corps Canada program – an employer-driven program for aspiring IT professionals that includes free training, paid internships, job placement and mentorship for underserved youth in the Greater Toronto and Hamilton Area (GTHA). This is a program under CivicAction’s Escalator Initiative which launched in September to uncover employment opportunities for youth facing barriers.

Leave a comment

December 5, 2014 · 4:59 am



Proteocyte has developed a test that can distinguishes between high risk precancerous oral lesions and those that pose low risk of developing into cancer.

Leave a comment

November 28, 2014 · 12:23 pm



ChipCare’s integrated point-of-care diagnostic and patient management system leverages recent advances in microfluidic and biomarker technologies to provide cell surface and blood analyte tests. Designed for community-level health workers, the Flow-LM is coupled with a mobile app to provide job task and training support, and to gather patient data. Wireless communication allows centrally located clinicians to advise front-line health workers, improving health system efficiency, decreasing cost and ultimately saving lives. Cloud EMR data aggregation provides health system managers and researchers with the information they need to make evidence-based program, funding and policy decisions.

Leave a comment

November 21, 2014 · 3:21 am


Performance Plants Wins 2014 Agrow Award for Best Industry Collaboration


Canadian agricultural biotechnology company Performance Plants Inc. (PPI) was awarded the Best Industry Collaboration award by Agrow at its annual awards ceremony.

PPI received the honour for its successful commercialization strategy, securing licensing and co-development agreements with collaborators such as Bayer CropScience,  Mahyco and Biocentury Transgene.  In conjunction with its partners, PPI is opening new markets, creating and strengthening both new and established alliances, forming a solid technology and product matrix for global commercialization.

PPI was also a finalist in a second of thirteen total categories:  Best R&D Pipeline.

Entries were judged by an independent panel consisting of senior experts worldwide.

Agrow is a leading industry provider of agricultural news, analysis and data services in crop protection and business intelligence world-wide and hosts leading industry awards for innovation and excellence each year.


November 20, 2014 · 8:55 pm


“Innovation means getting value out of ideas by converting them into usable products and services. Entrepreneurship is the driver of that process.”


Dr. Ilse Treurnicht
CEO of MaRS Centre
in the Discovery District
An incubator, innovation hub, business laboratory: all are accurate descriptors of the MaRS Centre, a 750,000-square-foot medical and biotech entrepreneurship facility located in the core of Toronto’s downtown medical-university business corridor. About 2,300 people work at the facility,
which opened in 2005 and will double in size this year.
As a matching service between aspiring entrepreneurs and advisors, purveyor of free market research, and liaison between start-ups and venture capitalists, MaRS is helping academics and researchers commercialize their groundbreaking discoveries. It could have no better location than
Toronto. Here’s why, according to CEO Dr. Ilse Treurnicht.




Leave a comment

August 15, 2014 · 3:26 pm


Future-proofing your research today



Provide a platform for automatically share and give notification of discoveries as they unfold via crowd-source knowledge engine.

Read More


Capital Lock up in Efficiency Innovation

Watch The Capitalist’s Dilemma – Prof. Clayton Christensen (HARVARD and OXFORD Universities)


Clayton Christensen on Religion and Capitalism

Leave a comment

August 7, 2014 · 11:55 pm



Prevent Fraud

If you’re like most companies, you spend too much time and money protecting your digital content – from websites to premium content to ads – from fraud. Are you getting the results you want?

Analytics You Can Trust

Ever wonder what your web analytics really look like? We don’t let bots through, so you get more accurate information on real human engagement.

Leave a comment

August 7, 2014 · 11:52 pm







Wave makes awesome, cloud-based, integrated software and tools for small businesses. So far, that includes Invoicing, Accounting, Payroll, Payments and more, plus Personal Finance Software, too.

Wave have been recognized with various industry awards, and have secured nearly $20 million in investment from some of the smartest investors in Toronto, Boston and Silicon Valley.


Leave a comment

August 7, 2014 · 10:43 pm




Wattpad is the world’s largest community of readers and writers

40 Billion Stories to read



Leave a comment

August 7, 2014 · 10:35 pm


Experimental Development & Scientific Research Tax Incentive Program of the FedGov Canada:

What the Program regarding INVESTMENT TAX CREDIT is looking for:


This could mean any type of works that is done in incubator labs in the Process of Technology Readiness (NASA 9 LEVELS) ?

>Market research or sales promotion
>quality control or routine testing
>research in social sciences or the humanities
>prospecting, exploring or drilling fr, or producing petroleum, natural gas, or minerals
>commercial production or use
>style changes
>routine data collection

by Nasrin Azad,

CEO OXFAZ Consulting

PGC Nanotechnology OXON

Leave a comment

July 13, 2014 · 3:23 pm

Oxbridge Biotech

Your global biotech hub.


Engage with over 20,000 members from academia and industry around the world to connect with the expertise and resources to move new ideas forward.




The world’s largest biotech business plan competition.
In conjunction with SR One, the venture capital arm of GlaxoSmithKline, OBR is seeking to fund tomorrow’s next generation of bio-entrepreneurs. The EU prize is £100k, the America prize is $150k, and both come with free lab-space for a year.

– See more at: http://www.oxbridgebiotech.com/#sthash.AsZbtJha.dpuf


Leave a comment

May 12, 2014 · 11:32 pm

Oxalys Innovation

Oxalys leaf 72dpi

Oxalys Pharmaceuticals is developing therapies to prevent, slow, or reverse the course of brain degeneration. Parkinson’s disease and Huntington’s disease are primary focus areas, and both have a strong unmet medical need.  The company’s drug discovery platform is designed to identify small molecules that suppress the toxic effects of mutations that have a causal role in neurodegeneration.  In this way, Oxalys is finding therapeutics that inhibit the underlying causes of diseases.



Leave a comment

May 12, 2014 · 11:19 pm



Intelligent Medical Imaging Systems

Deep Diagnostics uses state-of-the-art machine learning algorithms to substantially increase diagnostic accuracy in medical images.



1 Comment

May 11, 2014 · 11:15 am

STARTUPs at the Univ of Toronto


Read More….


Leave a comment

May 4, 2014 · 6:16 pm

Ontario Capital Growth Corporation (OCGC)




The Ontario Capital Growth Corporation (OCGC) was established by the Ontario Capital Growth Corporation Act, 2008 and was launched on February 27, 2009. The principal business of the OCGC is to manage the limited partner interests of the Government of Ontario in the Ontario Venture Capital Fund LP (OVCF) and the Northleaf Venture Catalyst Fund LP (NVCF), and to manage and operate the Ontario Emerging Technologies Fund (OETF).The Ontario Capital Growth Corporation (OCGC) was established by the Ontario Capital Growth Corporation Act, 2008 and was launched on February 27, 2009. The principal business of the OCGC is to manage the limited partner interests of the Government of Ontario in the Ontario Venture Capital Fund LP (OVCF) and the Northleaf Venture Catalyst Fund LP (NVCF), and to manage and operate the Ontario Emerging Technologies Fund (OETF).

About the Ministry of Research and Innovation

The Ministry of Research and Innovation supports world-class research, commercialization and innovation taking place across Ontario through a range of programs and services like the Ontario Research Fund, Innovation Demonstration Fund and Ontario Venture Capital Fund.


The Honorable Reza Moridi, Minister of Research and Innovation: We have a 10 year plan to build opportunity and secure our future.

Spread the word if you’re with us: http://www.ontario.ca/government/2014-ontario-budget


Leave a comment

May 2, 2014 · 7:56 pm





Leave a comment

April 26, 2014 · 9:00 pm



Shotlst makes visual collaboration simple. View progress photography, collaborate on individual images via annotation, commenting, and task assignment. Even allow field and site users to work with Shotlst through text message and email.

SHOTLIST span out of University of Toronto.


Leave a comment

April 25, 2014 · 6:08 pm


OxSyBio Raises $1.7 Million to Develop Synthetic 3D Printed Tissues For Organ and Skin Repairs


A University of Oxford spin-out, OxSyBio, will develop 3D printing techniques to produce tissue-like synthetic materials for wound healing and drug delivery.  In the longer term the company aims to print synthetic tissues for organ repair or replacement.

Isis Innovation, the University’s research commercialisation company announced today that OxSyBio has raised £1 million from IP Group plc, the developer of intellectual property based businesses, subject to the achievement of milestones. The new company will refine and advance the 3D droplet printing technology devised by Professor Hagan Bayley’s group at the University’s Department of Chemistry.




Leave a comment

April 18, 2014 · 6:22 pm


richard branson

Richard Branson’s first business venture was a magazine called Student at the age of 16. In 1970, he set up a mail-order record business. In 1972, he opened a chain of record stores, Virgin Records, later known as Virgin Megastores. Branson’s Virgin brand grew rapidly during the 1980s, as he set up Virgin Atlantic and expanded the Virgin Records music label.

According to the Forbes 2012 list of billionaires, Branson is the 6th richest citizen of the United Kingdom, with an estimated net worth of US$4.6 billion.

(Reuters) – Virgin America, the California-based airline, which was launched by Branson in 2007, would use capital from the potential listing to expand its fleet from 53 aircraft to near 100 over the next decade, according to the people quoted in report. (http://r.reuters.com/nej76v)



Leave a comment

February 23, 2014 · 3:16 pm

A Second American Century

Four Reasons to Believe in a Second American Century

by Harvard Business Review

Despite evidence to the contrary, Americans like to think our nation is about to be eclipsed. When I was a boy, people worried the Soviet Union would bury us. (How’d that work out?) Early in my career, a lot of commentators were sure Japan was on its way to becoming number one. Now it’s China’s turn to pull ahead.

I have nothing against China, or any other country. But overtake the United States? Not for a while. I’ve been watching the global economy for decades, and it seems to me that growth in the United States is about to speed up, while growth in the emerging markets is slowing down.

I make that statement in light of four powerful forces which are at work in the United States and which no other country can duplicate. American creativity remains unsurpassed. Manufacturing is undergoing a renaissance, building on a strong base. New technology has turned the U.S., however improbably, into the world’s largest energy producer. And capital is abundant.

American Creativity

If you doubt the force of America’s creativity, take a walk through the Kendall Square area of Cambridge, Massachusetts. In the shadow of MIT, there are dozens of large biotech and life sciences companies, and many dozens of startups. The neighborhood has become one of the most dynamic research centers in the world for the biosciences.

Because of Kendall Square’s concentration of talent, and its infrastructure, Novartis, the giant Swiss pharmaceutical company, moved nearly its entire research center here from Switzerland. When the French pharmaceutical company Sanofi bought Cambridge-based Genzyme, for $17 billion, it made Cambridge the Paris-based company’s most important research hub. These commercial companies are surrounded by academic research centers at MIT and Harvard and by a complex of private, non-profit research centers like the Broad Institute, the McGovern Institute, and many others, all working to transform medicine and extend the frontiers of science.

Other countries would love to have a cluster of research institutions like those located in Cambridge. And the fact is, Cambridge is just one of several such clusters in the United States. There is the Bay Area, encompassing the Universities of California at San Francisco and Berkeley as well as Stanford; the area around San Diego; Research Triangle in North Carolina; the area around Austin and Houston Texas; the I-95 corridor in New Jersey; as well as Seattle and many other areas of the country.

Manufacturing Renaissance

Americans are also fond of telling each other, “we don’t make anything here anymore.” The need to renew manufacturing was a big issue in the Presidential election of 2012. It might surprise you to learn that the United States remains the world’s preeminent producing nation, responsible for about 20 percent of the world’s goods – a little more than China produces.

China leads the world in low-margin electronics assembly, textiles, and some types of machinery; the United States, on the other hand, is a high-end producer. The average person assumes we don’t make anything because we don’t make a lot of what a typical consumer buys. Instead, we make jet turbines, helicopters, sophisticated airliners and business jets, electric generators, radar, chemicals and plastics, satellites, and all kinds of weapons.

Despite years of flat or declining budgets, the United States has retained its lead in space. Private companies like SpaceX are building some of the world’s most sophisticated and efficient rockets (and will resume launching people into space), while Orbital Sciences and the United Launch Alliance retain the lead in satellites.

Evidence abounds that even more manufacturing is coming to the United States. A new wave of it began before the crash in 2008, stopped while the world caught its breath, and is now resuming. The domestic automobile industry is in the midst of upgrading its manufacturing plants, foreign auto companies are expanding in the U.S., and companies like General Electric are making more of their white goods domestically. And what’s behind America’s return to manufacturing? Two things …

An Energy Bonanza       

First, America’s energy bonanza has changed the equation. This makes the United States, for many chemical companies, the preferred place to manufacture. Germany’s BASF, the world’s largest chemical company, has been investing $1 billion a year in the United States to expand its facilities and take advantage of America’s cheap natural gas to use as a feedstock. Dow Chemical is expanding its investment in the U.S. for the same reason.

How cheap is America’s natural gas? Over the past year, it has on average cost around $4 to buy a million BTUs worth of natural gas in the U.S. The same amount of natural gas cost about $14 in Europe, $15 in China, and about $16 in Japan. Not only can natural gas be used as a feedstock for chemicals, fertilizers, pesticides, paints, plastics, and cosmetics, in 2013 the Cummins Corp. an engine manufacturer, began building an engine for long-haul trucks optimized to run on natural gas.

America’s energy bonanza is not a short-lived phenomenon. It could be with us for a century, perhaps even longer. As it develops, the U.S. will shift from energy importer to energy independent, then to net energy exporter. As that happens, the trade deficit will fall. Indeed, it could even turn positive.

Abundant Capital

The Great Recession did what recessions tend to do. It shifted debt from the private side of the country’s balance sheet to the public side. The result has been that the government has a lot of debt, while households are in better shape than in decades. Today, households use a smaller share of their incomes to pay off their credit cards, mortgages, and other debts than at any time in the last 35 years. Americans are saving money at very high rates.

While households have been trimming down their debt, the value of people’s savings, investments, and retirement accounts has recovered from the recessionary low. In addition, since falling during the Great Recession, home prices are recovering, too.

Partly as a result of the slowdown, partly as a result of increases in productivity, and partly as a result of renegotiating their debt at highly favorable rates in the aftermath of the downturn, companies are flush with cash. Although estimates vary, American companies have between $4 and $5 trillion in liquid assets, a sum greater than the size of the German economy.

*   *   *   *   *   *

America’s continued progress will be driven by creativity, manufacturing excellence, abundant energy, and large capital reserves. Whereas some countries might enjoy the effects of one or two of these forces, no country but the U.S. has all four going for them. For the first time since the Great Recession, the economic winds are at our backs.

I’m not suggesting that the U.S. doesn’t have problems. We certainly have our share. What I will say is that we now have resources available to fix those problems. While I’m at it, I’ll also note the good news that Americans are personally healthier than in decades. It’s enough to make you want to believe in a new American Century.


Leave a comment

February 14, 2014 · 2:49 pm


iphoneEnabling information to be transferred simply and securely so that mobile phone users can safely pay each other and merchants is the mission of the latest spin-out company from the University of Oxford, Oxcept.

Isis Innovation, Oxford’s technology commercialisation company, announced that Oxcept is gearing up to provide a peer-to-peer payment app to mobile users. Underlying the new app is the invention at Oxford’s Department of Computer Science of a family of security protocols which allow users to create a new secure network, or to secure an initially insecure network.

The technology is purely software based, and does away with the need for any cords and network connections. There is no swiping, scanning or card reading. No pass codes, account information or credit card details are disclosed. Once both parties have downloaded the app the payer authenticates the payee and authorises a payment.

Security protocols are the rules that govern the use of algorithms to ensure that data is securely transmitted between two or more parties, some of which require human involvement, some of which don’t. The business idea went forward with  $1 million from the US Navy and £100,000 from UK Ministry of Defence helping to turn daydreams into a real-life family of human interactive security protocols (HISP).




Leave a comment

January 30, 2014 · 2:48 pm



The Cost of Software Bugs

According to a report by the University of Cambridge, programmers spend nearly half their time correcting code and fixing bugs. The report estimates software bugs cost nearly $312 billion a year.


Leave a comment

January 29, 2014 · 5:46 pm

Induce Biologics



How can surgeons avoid having to remove bone from a patient’s leg to replace bone loss caused by conditions such as cancer? Induce Biologics Inc. works to provide a solution to this medical challenge. The company’s founders, Dr. Sean Peel and Dr. Cameron Clokie are working with the RIC Centre to bring their innovative bone regenerative products, URIST™ and URIST™ Plus, to the market. According to Dr. Peel, many current products used by surgeons to regenerate bone have the consistency of “wet toilet paper,” making them incredibly difficult to handle and place in the patient. What makes Induce Biologics unique is that their products have the consistency of putty.



Leave a comment

January 28, 2014 · 6:08 pm


Crowdmark announces new partnership with Ricoh Canada Inc.

Crowdmark Logo: Grade BetterCrowdmark, a MaRS Innovation and University of Toronto start-up incubated through the UTEST program, has reached a deal with Ricoh Canada Inc.

Announced January 20, 2014, the deal outlines national printing and scanning service for Crowdmark customers, with U.S. discussions coming up in the future, to improve the start-up’s online marking process for teachers.

Here’s an excerpt from the release (emphasis ours):

Ricoh LogoToronto, Ontario (January 20, 2014) – Crowdmark Inc., a software company that delivers an ultra-scalable collaborative assessment platform to educators worldwide, announced today that it has entered into an agreement with Ricoh Canada Inc., to support Crowdmark’s customers, and with plans to explore additional enhancements to the relationship that will deliver additional client benefits.

Leave a comment

January 27, 2014 · 2:49 pm

Disruptive Innovation Growth

Clayton Christensen (Oxford and Harvard Universities)



Leave a comment

December 1, 2013 · 1:07 pm


chose an innovation








Leave a comment

October 22, 2013 · 3:05 pm

O M Diagnostics

spacer spacerspacer

Oxford Medical Diagnostics develops and supplies breath analysis technologies for rapid, accurate, and low-cost monitoring of diseases and metabolic functions.

The current focus of OMD’s work is the development of a breath test to indirectly measure blood ketones. This test is designed to assist type 1 diabetics with their condition and its complications, particularly diabetic ketoacidosis, the main cause of mortality in diabetics. It is envisaged that this will provide a completely non-invasive, more user-friendly and accurate test compared with the current standard blood ketone strips, which require blood samples from a painful finger stick.

Developed within Professor Gus Hancock’s research group at the University of Oxford, the Company’s major proprietary technology – Cavity Enhanced Absorption Spectroscopy – allows the measurement of acetone at sub-parts-per-million levels in breath. The technology allows for sensitivity far beyond the current industry standard. There is also significant potential to exploit breath acetone measurements in a separate device as a surrogate marker for blood glucose.

OMD has brought together a highly experienced management team to realise the significant potential of the CEAS technology platform. The Company maintains close links with the University of Oxford and academics around the world.


Leave a comment

October 22, 2013 · 3:00 pm




SafeClickTM is Future  Injection Technologies’ (FIT’s) family of novel and  proprietary single use
disposable auto-injectors that allows self-administration of viscous biological and  standard therapies via regulatory standard  pre-filled syringes.


Leave a comment

October 22, 2013 · 2:53 pm


Epicardio_logo_x180_300dpiEpicardio key innovation is based on software solutions that enable real-time 3D simulations to execute on common desktop/laptop computers and the iPad. For the first time, medical “learning-by-doing” is accessible on widely available consumer devices, via standard internet connections. Epicardio simulators bridge the training gap between theory and medical practice by enabling trainee doctors to gain direct experience of how disease can cause changes in organ function. The solution is scalable to a wide range of specialist and non-specialist training, e.g. cardiology, orthopaedics, neurology, endoscopies, etc. The innovative features of the Epicardio computer based simulation are being patented and further R&D is focused on developing the technology into a complete patient-specific diagnostic solution for cardiology.



Leave a comment

October 22, 2013 · 2:50 pm


focus is the secure and industrialized Information Management of Omics projects. Enabling science teams to store, create, annotate, track data and pipelines in a web based environment. Using a hybrid cloud approach we can seamlessly complement your existing infrastructure investments. We make your Omics data assets more portable, reproducible and reusable. The benefits are accelerated scientific research and improved effectiveness and efficiency.


Leave a comment

October 22, 2013 · 2:46 pm

BioMimOx Ltd

BioMimOx is an early stage biotech company investigating a proprietary peptide display platform for selection and affinity maturation of peptide aptamers and antibodies for use in research, diagnostics and biotherapeutics. We are also to investigate proprietary peptide aptamers and library construction as next generation affinity ligand binders.


Leave a comment

October 22, 2013 · 2:42 pm


Introducing the Freescale Freedom Development Platform FRDM-KL25Z

Freescale Freedom Boards distributed by Mouser Electronics – Product Overview

Leave a comment

October 22, 2013 · 2:36 pm

Absolute Antibody


Absolute Antibody offers engineered antibodies for all through it’s Recombinant Antibody Production, Antibody Engineering and Hybridoma Sequencing services.  A catalog of reagents for research and diagnostic use is launching soon.


Leave a comment

October 22, 2013 · 2:32 pm

Bio X Ltd.

Oxford Chilli Tester Goes Into ManufactureChilli sensor developed at the University of Oxford is to be manufactured by Singapore spin-out, Bio-X (S) Pte. Ltd. to bring standardisation for heat in the food industry. The mass-produced sensor could see the ubiquitous chilli symbols on food packaging replaced by Scoville units. The sensor measures the levels of capsaicinoids, chemicals in chillies that gives us the characteristic ‘heat’. The most common method of assessing the heat at the moment involves a panel of tasters – which takes time, incurs costs and often yields variable results. The handheld Chilli Tester uses nanotechnology to give an accurate measure in minutes.
The technology is licensed from Isis Innovation, the Technology Transfer Company of Oxford University, by Bio-X Ltd., a Singapore company that already deals with chemical sensors. The CEO of Bio-X (S) Pte. Ltd., Mr. Donald Foo, explained the attraction of chilli sensor technology: “With a Chilli Tester to measure the spiciness and grade products, it will provide a common understanding for heat. Spiciness is subjective and varies from culture to culture. An Asian’s tolerance for spiciness is generally different from a European’s.”

Leave a comment

October 1, 2013 · 11:58 am


At OTI Lumionics, we are working on unlocking the full potential of OLED lighting and displays, through innovative equipment, materials, and process technology.

Our patented solutions eliminate the bottleneck in traditional OLED manufacturing, enabling low-cost and high-volume mass production.




1 Comment

September 14, 2013 · 9:51 pm

Theralase Inc

laura laser

Toronto-based Theralase Inc. has collaborated with Ontario Centres of Excellence (OCE) and the University Health Network (UHN) for over a decade to develop its industry leading line of Low Level Laser Therapy products used in hospitals and medical clinics across North America.

Designed to treat wounds, increase tissue regeneration and reduce inflammation and pain, Theralase is the creator of one of only three FDA NHN (non-heating) approved therapeutic medical lasers licensed in the US and the only therapeutic laser system approved for chronic knee pain.


Toronto-based Theralase Inc. has collaborated with Ontario Centres of Excellence (OCE) and the University Health Network (UHN) for over a decade to develop its industry leading line of Low Level Laser Therapy products used in hospitals and medical clinics across North America.

Designed to treat wounds, increase tissue regeneration and reduce inflammation and pain, Theralase is the creator of one of only three FDA NHN (non-heating) approved therapeutic medical lasers licensed in the US and the only therapeutic laser system approved for chronic knee pain.

– See more at: http://www.oce-ontario.org/meet-our-companies/success-story/2012/01/09/theralase#sthash.iZfiYzy0.dpufToronto-based Theralase Inc. has collaborated with Ontario Centres of Excellence (OCE) and the University Health Network (UHN) for over a decade to develop its industry leading line of Low Level Laser Therapy products used in hospitals and medical clinics across North America.

Designed to treat wounds, increase tissue regeneration and reduce inflammation and pain, Theralase is the creator of one of only three FDA NHN (non-heating) approved therapeutic medical lasers licensed in the US and the only therapeutic laser system approved for chronic knee pain.

– See more at: http://www.oce-ontario.org/meet-our-companies/success-story/2012/01/09/theralase#sthash.iZfiYzy0.dpuf

Leave a comment

September 2, 2013 · 4:15 pm




ChipCare is a privately held, for profit, corporation developing a handheld cell analyzer based on mobile technology. Its vision is to become a global leader in developing and providing point-of-care (POC) testing solutions for global health.

ChipCare’s mission is to bring lab-based medical tests to patients, enabling every person around the world to have easy access to state-of-the-art blood tests. Continue reading

Leave a comment

August 31, 2013 · 9:44 pm



CCRM’s mission is to create and sustain a global nexus for Regenerative Medicine (RM) commercialization by unifying dynamic business leadership with high value innovative translational technology platforms based on demonstrated excellence in fundamental stem cell and biomaterial science.


Leave a comment

August 29, 2013 · 4:50 pm



Established in July 2008 with a research base in Oxford, UK and a clinical base in Philadelphia, US, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease.  It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses.  Adaptimmune undertakes all of its own research and development using proprietary T cell receptor engineering technology co-developed with its sister company Immunocore Ltd (formerly Avidex/MediGene) and exclusively licensed for T cell therapy.  Backed by private investors, Adaptimmune is now in the clinic in the US, in HIV as well as multiple cancer indications with its engineered TCR to the NY-ESO-1/LAGE-1 cancer testis antigen.

Adaptimmune’s Mission Statement

Adaptimmune’s mission is to develop disruptive therapy for serious disease using engineered T cells. The Company’s core technology is the development of affinity-enhanced T cell receptors (TCR) for use in adoptive T cell therapy.

The Adaptimmune product is a T cell expressing a modified TCR to recognize a tumour antigen (epitope) associated with a HLA molecule.

Leave a comment

August 29, 2013 · 4:48 pm

Oxford Immunotec



Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology.  The company was founded in 2002 based on world-leading research at the University of Oxford.  The European headquarters are located in Abingdon, UK and the North American headquarters are located in Marlborough, MA USA.

T-Cell Xtend is an antibody complex directed against specific cell surface antigens
on human blood cells
• T-Cell Xtend cross-links selected white cells, that may interfere with ELISPOT
assays, with red blood cells
• This cross-linking increases the density of selected cells so that they form a pellet
when applied to a density gradient

The use of T-Cell Xtend allows the T-SPOT®.TB assay to be performed on blood samples up to 32 hours after venepuncture without any change in accuracy of the test.


1 Comment

August 29, 2013 · 4:25 pm